Evasc Neurovascular Announces Enrollment of First Patient in the French eCLIPs™ Safety, Feasibility and Efficacy Study (EESIS-FR)
13.1.2022 09:05:00 EET | Business Wire | Press release
Evasc Neurovascular, a pioneer in the development of disruptive endovascular treatments for cerebral aneurysms, announced today the enrollment of the first patient in its French eCLIPs™ Safety, Feasibility and Efficacy Study (EESIS-FR). The study will be conducted in France with the objective to evaluate the technical feasibility, safety, and efficacy of the eCLIPs products for the treatment of bifurcation aneurysms. The eCLIPs device has been granted ‘innovative’ status in the French Forfait Innovation program and the study is partially funded by the French National Authority for Health (HAS) within this program. Up to 28 neuro-interventional sites in France will enroll patients in this study.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111006183/en/
Announcing the enrollment of the first patient in Evasc Neurovascular's French eCLIPs™ Safety, Feasibility and Efficacy Study (EESIS-FR) (Photo: Evasc Neurovascular)
The procedural success of the second generation eCLIPs Bifurcation Remodelling System will be evaluated to determine its feasibility and safety will be measured as of a major stroke or death within 30 days, or major territorial stroke or neurological death within one year. Additional endpoints will be evaluated, and data collected to assess the procedural success and to collect efficacy information on the other eCLIPs products.
“I am pleased to have enrolled the first patient in this important clinical study to help further the clinical understanding of the real-world effectiveness of the second generation eCLIPs Aneurysm Treatment System. We have seen an enormous improvement in the second generation eCLIPs delivery system: stability and placement within eight minutes is a game-changer in the neurointerventional practise,” said Dr. Raphael Blanc, Principal Investigator of the study and Consultant Interventional Neuroradiologist and Deputy Head of the Department of Interventional Neuroradiology at Rothschild Foundation Hospital, Paris, France.
“Thanks to our French partners, we have achieved this significant milestone after many years of hard work,” said Dr. Donald Ricci, President and Chief Executive Officer of Evasc Neurovascular.
About the eCLIPs Aneurysm Treatment System
eCLIPs is a non-tubular endovascular device currently targeted for use in challenging wide-neck bifurcations, using technology designed to treat 95% of cerebral aneurysm cases. The unique eCLIPs design provides not only coil retention, but also flow diversion at the neck. eCLIPs avoids dangerous entry into the dynamic, fragile environment of the aneurysm sac while leaving side branches unencumbered and providing a platform for endothelial growth across the bifurcation neck.
About Evasc
Evasc Neurovascular is a privately held medical device company focused on the development of disruptive endovascular treatments for cerebral aneurysms. Evasc Neurovascular is headquartered in Vancouver, Canada. For additional information, please visit evasc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220111006183/en/
Contact information
Scott Wilson, +1 (604) 742-3811, wilson@evasc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Riskified Unveils Next-Generation AI Suite at Ascend 2026, Empowering Merchants with Unprecedented Visibility and Control Over Ecommerce Risk6.5.2026 16:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced a major leap forward in its AI platform capabilities, introducing a powerful suite of control and empowerment tools designed to give merchant fraud teams complete visibility into risk patterns and identity behavior, conversational AI-driven insights, and the ability to surgically tailor their risk strategies. The innovation suite was announced onstage at Ascend 2026, Riskified’s premier global summit series, taking place May 4-6, 2026, at the Conrad New York Downtown in Manhattan, NY. With global ecommerce continuing to expand and losses from AI-driven fraud attacks projected to spike, particularly with the rise of agentic commerce, where AI bots may conduct transactions on behalf of consumers, accurate fraud decisions are fundamental, but are no longer enough. Today, more than ever, sophisticated fraud and risk teams need to understand the why behind every transaction and pattern, and req
Twilio’s Next Generation Platform: An Infrastructure Layer for Every Conversation in the Agentic Era6.5.2026 16:00:00 EEST | Press release
Twilio (NYSE: TWLO), the infrastructure for customer engagement in the AI era, kicked off its user conference, SIGNAL, by unveiling its next generation platform capabilities for the agentic era. Generally available today, Conversation Memory, Conversation Orchestrator, Conversation Intelligence, and Agent Connect combine to turn disparate interactions into continuous, intelligent, and personal conversations across humans, agents, and systems. “The agentic era is here. Agents are joining conversations alongside the people they represent, and modern customer engagement requires an infrastructure that serves both equally,” said Khozema Shipchandler, Chief Executive Officer at Twilio. “Twilio’s new platform is the foundational infrastructure layer that makes every conversation persistent, contextual, and actionable – ensuring interactions feel like part of one continuous relationship." An Infrastructure Layer for Every Conversation Every business runs on conversations. Today, however, busi
Vultr, SUSE & Supermicro Debut Unified Cloud-to-Edge Architecture for Global AI Scaling6.5.2026 15:00:00 EEST | Press release
Vultr, the world's largest privately-held cloud infrastructure company, in collaboration with SUSE and Supermicro, today announces a strategic architectural framework designed to solve the complexities of deploying and operating AI workloads across distributed environments. As AI moves closer to the point of data creation - from manufacturing floors to retail storefronts - organizations face significant challenges in latency, cost and operational consistency. This joint initiative provides a seamless, Cloud-to-Edge pipeline that integrates high-performance hardware, localized cloud infrastructure, and unified Kubernetes management. The partnership addresses the reality that sending all data back to a central cloud is no longer viable for real-time AI. The solution breaks down the infrastructure into three critical layers: The Cloud and Near-Edge - Enterprises can deploy regional Kubernetes-based AI clusters closer to their users by leveraging Vultr’s 33 global cloud data center regions
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program6.5.2026 15:00:00 EEST | Press release
Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program. With deep expertise across diverse pathology and multimodal data, and a global data network spanning academic institutions, hospitals, and laboratories, Waiv has a proven track record delivering AI-powered biomarker solutions across the full drug development lifecycle. Under the collaboration, Waiv will apply its end-to-end computational pathology platform to early phase data. This includes tumor microenvironment (TME) analysis across both hematoxylin and eosin (H&E) and immunohistochemistry (IHC) stained samples, as well as biomarker discovery and outcome prediction capabilities aimed at identifying biomarkers of treatment response ahead of next clinical trial phases. Purpose-built AI approach tackles one of pharma's hardest challenges: b
Elisa Expands PON Deployment with Vecima’s All-PON™ Shelf, Delivering 10G Fiber Services in Estonia6.5.2026 14:30:00 EEST | Press release
Vecima Networks Inc. (TSX: VCM) announced today that leading telecommunications operator Elisa has deployed Vecima’s Entra EXS1610 All-PON™ Shelf for 10G Fiber-to-the-Home (FTTH) services for its subscribers in Estonia. In Estonia’s competitive broadband market, Elisa brings highly innovative solutions to its subscribers. Vecima’s EXS1610 supports multiple deployment use cases, including greenfield, targeted brownfields, rural edge-outs, hybrid fiber-coax (HFC) overbuilds, footprint extensions, and hub collapses. Its compact shelf footprint can help reduce operating costs and allow operators to deploy anywhere – for maximum flexibility, including data centers, remote cabinets, the headend, and multi-dwelling units. The Entra EXS1610 All-PON Shelf features: 16 x PON ports: 10G-EPON, XGS-PON, and Combo XGS-PON & GPON Temperature-hardened for outside plant deployments Multi-vendor optical network terminal (ONT) interoperability Uplink optics: 2 x 100/40G & 2 x 25/10G with broad third-part
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom